Literature DB >> 19922971

Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Abdul S Yunus1, Trent P Jackson, Katherine Crisafi, Irina Burimski, Nicole R Kilgore, Dorian Zoumplis, Graham P Allaway, Carl T Wild, Karl Salzwedel.   

Abstract

Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection in infants, immunocompromised patients, and the elderly. The RSV fusion (F) protein mediates fusion of the viral envelope with the target cell membrane during virus entry and is a primary target for antiviral drug and vaccine development. The F protein contains two heptad repeat regions, HR1 and HR2. Peptides corresponding to these regions form a six-helix bundle structure that is thought to play a critical role in membrane fusion. However, characterization of six-helix bundle formation in native RSV F protein has been hindered by the fact that a trigger for F protein conformational change has yet to be identified. Here we demonstrate that RSV F protein on the surface of infected cells undergoes a conformational change following exposure to elevated temperature, resulting in the formation of the six-helix bundle structure. We first generated and characterized six-helix bundle-specific antibodies raised against recombinant peptides modeling the RSV F protein six-helix bundle structure. We then used these antibodies as probes to monitor RSV F protein six-helix bundle formation in response to a diverse array of potential triggers of conformational changes. We found that exposure of 'membrane-anchored' RSV F protein to elevated temperature (45-55 degrees C) was sufficient to trigger six-helix bundle formation. Antibody binding to the six-helix bundle conformation was detected by both flow cytometry and cell-surface immunoprecipitation of the RSV F protein. None of the other treatments, including interaction with a number of potential receptors, resulted in significant binding by six-helix bundle-specific antibodies. We conclude that native, untriggered RSV F protein exists in a metastable state that can be converted in vitro to the more stable, fusogenic six-helix bundle conformation by an increase in thermal energy. These findings help to better define the mechanism of RSV F-mediated membrane fusion and have important implications for the identification of therapeutic strategies and vaccines targeting RSV F protein conformational changes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922971      PMCID: PMC2789909          DOI: 10.1016/j.virol.2009.10.040

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  79 in total

1.  Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

2.  Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.

Authors:  P Chambers; C R Pringle; A J Easton
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

3.  Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

Authors:  S Levine; R Klaiber-Franco; P R Paradiso
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

Review 4.  Paramyxovirus fusion: a hypothesis for changes.

Authors:  R A Lamb
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

5.  Conformational change of the coronavirus peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and virus-induced cell fusion.

Authors:  L S Sturman; C S Ricard; K V Holmes
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion.

Authors:  B R Heminway; Y Yu; Y Tanaka; K G Perrine; E Gustafson; J M Bernstein; M S Galinski
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

7.  Characteristics of fusion of respiratory syncytial virus with HEp-2 cells as measured by R18 fluorescence dequenching assay.

Authors:  N Srinivasakumar; P L Ogra; T D Flanagan
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

8.  Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage.

Authors:  K Anderson; E J Stott; G W Wertz
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

View more
  17 in total

Review 1.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

Review 2.  Impact of pollution, climate, and sociodemographic factors on spatiotemporal dynamics of seasonal respiratory viruses.

Authors:  Chantel Sloan; Martin L Moore; Tina Hartert
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  Spatiotemporal patterns of infant bronchiolitis in a Tennessee Medicaid population.

Authors:  Chantel D Sloan; Tebeb Gebretsadik; Pingsheng Wu; Kecia N Carroll; Edward F Mitchel; Tina V Hartert
Journal:  Spat Spatiotemporal Epidemiol       Date:  2013-09

4.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

5.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

6.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Authors:  Ivy Widjaja; Oliver Wicht; Willem Luytjes; Kees Leenhouts; Peter J M Rottier; Frank J M van Kuppeveld; Bert Jan Haijema; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

7.  Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Authors:  Michael B Battles; Johannes P Langedijk; Polina Furmanova-Hollenstein; Supranee Chaiwatpongsakorn; Heather M Costello; Leen Kwanten; Luc Vranckx; Paul Vink; Steffen Jaensch; Tim H M Jonckers; Anil Koul; Eric Arnoult; Mark E Peeples; Dirk Roymans; Jason S McLellan
Journal:  Nat Chem Biol       Date:  2015-12-07       Impact factor: 15.040

8.  A Decrease in Temperature and Humidity Precedes Human Rhinovirus Infections in a Cold Climate.

Authors:  Tiina M Ikäheimo; Kari Jaakkola; Jari Jokelainen; Annika Saukkoriipi; Merja Roivainen; Raija Juvonen; Olli Vainio; Jouni J K Jaakkola
Journal:  Viruses       Date:  2016-09-02       Impact factor: 5.048

9.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation.

Authors:  Christopher C Stobart; Christina A Rostad; Zunlong Ke; Rebecca S Dillard; Cheri M Hampton; Joshua D Strauss; Hong Yi; Anne L Hotard; Jia Meng; Raymond J Pickles; Kaori Sakamoto; Sujin Lee; Michael G Currier; Syed M Moin; Barney S Graham; Marina S Boukhvalova; Brian E Gilbert; Jorge C G Blanco; Pedro A Piedra; Elizabeth R Wright; Martin L Moore
Journal:  Nat Commun       Date:  2016-12-21       Impact factor: 14.919

10.  Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Authors:  Dirk Roymans; Sarhad S Alnajjar; Michael B Battles; Panchan Sitthicharoenchai; Polina Furmanova-Hollenstein; Peter Rigaux; Joke Van den Berg; Leen Kwanten; Marcia Van Ginderen; Nick Verheyen; Luc Vranckx; Steffen Jaensch; Eric Arnoult; Richard Voorzaat; Jack M Gallup; Alejandro Larios-Mora; Marjolein Crabbe; Dymphy Huntjens; Pierre Raboisson; Johannes P Langedijk; Mark R Ackermann; Jason S McLellan; Sandrine Vendeville; Anil Koul
Journal:  Nat Commun       Date:  2017-08-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.